Download Free Sample Report

RNA-based biopharmaceuticals, which includes therapeutics and vaccines, is a relatively new class of treatment and prophylactic for a number of chronic and rare diseases, including cancer, diabetes, tuberculosis and certaincardiovascular conditions.
This report contains market size and forecasts of RNA-Based Therapeutics and Vaccines in Global, including the following market information:

• Global RNA-Based Therapeutics and Vaccines Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global RNA-Based Therapeutics and Vaccines market was valued at 26 million in 2021 and is projected to reach US$ 558.8 million by 2028, at a CAGR of 54.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
RNA-Based Therapeutics Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of RNA-Based Therapeutics and Vaccines include Alnylam Pharmaceuticals, Arbutus Biopharma, Arrowhead Pharmaceuticals, BioNTech, CureVac, Dicerna Pharmaceuticals, Regulus Therapeutics, Marina Biotech and MiRagen Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the RNA-Based Therapeutics and Vaccines companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global RNA-Based Therapeutics and Vaccines Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global RNA-Based Therapeutics and Vaccines Market Segment Percentages, by Type, 2021 (%)

• RNA-Based Therapeutics
• RNA-Based Vaccines

Global RNA-Based Therapeutics and Vaccines Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global RNA-Based Therapeutics and Vaccines Market Segment Percentages, by Application, 2021 (%)

• Oncology
• Immunology
• Ophthalmology
• Cardiovascular Diseases
• Infectious Diseases
• Genetic Diseases
• Others

Global RNA-Based Therapeutics and Vaccines Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global RNA-Based Therapeutics and Vaccines Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies RNA-Based Therapeutics and Vaccines revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies RNA-Based Therapeutics and Vaccines revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Alnylam Pharmaceuticals
• Arbutus Biopharma
• Arrowhead Pharmaceuticals
• BioNTech
• CureVac
• Dicerna Pharmaceuticals
• Regulus Therapeutics
• Marina Biotech
• MiRagen Therapeutics
• Moderna Therapeutics
• Quark Pharmaceuticals
• Roche
• Sylentis